Disparities in survival by insurance status in follicular lymphoma.

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma and most common indolent non-Hodgkin lymphoma. Lower socioeconomic status is associated with poor outcomes in FL, suggesting that access to care is an important prognostic factor; however, the association between insurance status and FL survival has not been sufficiently examined. The National Cancer Database, a nationwide cancer registry, was used to evaluate 43 648 patients with FL diagnosed between 2004 and 2014. All analyses were performed on 2 cohorts segmented at age 65 years to account for changes in insurance status with Medicare eligibility. Cox proportional hazard models calculated hazard ratios (HRs) with confidence intervals (CIs) for the association between insurance status and overall survival (OS) controlling for the available sociodemographic and prognostic factors. Kaplan-Meier curves display outcomes by insurance status for patients covered by private insurance, no insurance, Medicaid, or Medicare. When compared with patients younger than age 65 years with private insurance, patients younger than age 65 years with no insurance (HR, 1.96; 95% CI, 1.69-2.28), with Medicaid (HR, 1.82; 95% CI, 1.57-2.12), and with Medicare (HR, 1.96; 95% CI, 1.71-2.24) had significantly worse OS after adjusting for sociodemographic and prognostic factors. Compared with patients age 65 years or older with private insurance, those with Medicare only (HR, 1.28; 95% CI, 1.17-1.4) had significantly worse OS. For adults with FL, expanding access to care through insurance has the potential to improve outcomes.

[1]  B. Sommers Why Health Insurance Matters-and Why Research Evidence Should Too. , 2017, Academic medicine : journal of the Association of American Medical Colleges.

[2]  Atul A. Gawande,et al.  Health Insurance Coverage and Health — What the Recent Evidence Tells Us , 2017, The New England journal of medicine.

[3]  G. Salles,et al.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. , 2017, Blood.

[4]  B. Esmaeli,et al.  Prognostic Value of the Staging System for Eyelid Tumors in the 7th Edition of the American Joint Committee on Cancer Staging Manual. , 2017, Ophthalmic plastic and reconstructive surgery.

[5]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[6]  A. Haynes,et al.  Impact of Health Insurance Expansion on the Treatment of Colorectal Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Cerhan,et al.  Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era , 2016, British journal of haematology.

[8]  A. Jemal,et al.  Association Between the Affordable Care Act Dependent Coverage Expansion and Cervical Cancer Stage and Treatment in Young Women. , 2015, JAMA.

[9]  L. Harrison,et al.  Disparities in survival by insurance status in patients with Hodgkin lymphoma , 2015, Cancer.

[10]  L. Sehn,et al.  Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Jeffery A. Jones,et al.  A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. , 2015, Blood.

[13]  J. Cerhan,et al.  Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era , 2014 .

[14]  A. Jemal,et al.  Insurance status is related to diffuse large B‐cell lymphoma survival , 2014, Cancer.

[15]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[16]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[17]  Summer S. Han,et al.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.

[18]  S. Montoto,et al.  Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Epstein,et al.  Mortality and access to care among adults after state Medicaid expansions. , 2012, The New England journal of medicine.

[20]  Amy Y. Chen,et al.  Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[21]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[22]  Adele Seniori Costantini,et al.  InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. , 2010, Blood.

[23]  E. Ward,et al.  The Association of Insurance and Stage at Diagnosis Among Patients Aged 55 to 74 Years in the National Cancer Database , 2010, Cancer journal.

[24]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Elting,et al.  Factors Associated With Immunotherapy Use Among Newly Diagnosed Cancer Patients , 2009, Medical care.

[26]  C. Clarke,et al.  Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Rossi,et al.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.

[28]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Amy Y. Chen,et al.  Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. , 2008, The Lancet. Oncology.

[30]  A. Bleyer,et al.  Delays in cancer diagnosis in underinsured young adults and older adolescents. , 2007, The oncologist.

[31]  J. Gribben How I treat indolent lymphoma. , 2007, Blood.

[32]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[34]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Solal-Céligny Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[36]  Indiana Strombom,et al.  Socioeconomic Risk Factors for Breast Cancer: Distinguishing Individual- and Community-Level Effects , 2004, Epidemiology.

[37]  C. Bradley,et al.  Late Stage Cancers in a Medicaid-insured Population , 2003, Medical care.

[38]  S. Robert Community-level socioeconomic status effects on adult health. , 1998, Journal of health and social behavior.

[39]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[40]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[42]  S. Long,et al.  Access To Care And Affordability Have Improved Following Affordable Care Act Implementation; Problems Remain. , 2016, Health affairs.

[43]  Andrew Ma,et al.  Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer Registries , 2013, Annals of Surgical Oncology.

[44]  Michael Halpern,et al.  Association of Insurance with Cancer Care Utilization and Outcomes , 2008, CA: a cancer journal for clinicians.

[45]  T. Lister,et al.  Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.